ALLHAT: What has it taught us so far?

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 7, 2004, Pages 719-720

  Leenen, Frans H H ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; THIAZIDE DIURETIC AGENT;

ALLERGIC REACTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG CHOICE; DRUG INDICATION; GASTROINTESTINAL HEMORRHAGE; GOUT; HEART PROTECTION; HUMAN; HYPERTENSION; SHORT SURVEY;

EID: 4844226726     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1031010     Document Type: Short Survey

References (9)

1. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
2. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055-76.
3. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med 2003;139:777-80.
4. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD, et al. Validation of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT): participants assigned to doxazosin and chlorthalidone. Curr Control Trials Cardiovasc Med 2002;3:10-19.
5. Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P, for the ALLHAT Collaborative Research Group. ALLHAT: Setting the record straight. Ann Intern Med 2004;141:39-46.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published errata in JAMA 2003;289(2):178 and 2004;291 (18):2196]. JAMA 2002;288:2981-97.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published errata in JAMA 2003;289(2):178 and 2004;291 (18):2196]. JAMA 2002;288:2981-97.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published errata in JAMA 2003;289(2):178 and 2004;291 (18):2196]. JAMA 2002;288:2981-97.
9. Asch SM, Kerr EA, Lapuerta P, Law A, McGlynn EA. A new approach for measuring quality of care for women with hypertension. Arch Intern Med 2001;161:1329-35.